 SAN CLEMENTE, Calif.--BUSINESS WIRE--Glaukos Corporation NYSE: GKOS, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure IOP in a 24-month interim analysis of the ongoing 36-month Phase 2b clinical trial conducted under a U.S. Investigat 